[go: up one dir, main page]

AU2003266302A1 - Method for the diagnosis of alzheimer disease - Google Patents

Method for the diagnosis of alzheimer disease

Info

Publication number
AU2003266302A1
AU2003266302A1 AU2003266302A AU2003266302A AU2003266302A1 AU 2003266302 A1 AU2003266302 A1 AU 2003266302A1 AU 2003266302 A AU2003266302 A AU 2003266302A AU 2003266302 A AU2003266302 A AU 2003266302A AU 2003266302 A1 AU2003266302 A1 AU 2003266302A1
Authority
AU
Australia
Prior art keywords
diagnosis
alzheimer disease
alzheimer
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003266302A
Inventor
Andre Schrattenholz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ProteoSys AG
Original Assignee
ProteoSys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ProteoSys AG filed Critical ProteoSys AG
Publication of AU2003266302A1 publication Critical patent/AU2003266302A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2003266302A 2002-08-23 2003-08-21 Method for the diagnosis of alzheimer disease Abandoned AU2003266302A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40530002P 2002-08-23 2002-08-23
US60/405,300 2002-08-23
PCT/EP2003/009300 WO2004019045A2 (en) 2002-08-23 2003-08-21 Method for the diagnosis of alzheimer disease

Publications (1)

Publication Number Publication Date
AU2003266302A1 true AU2003266302A1 (en) 2004-03-11

Family

ID=31946851

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003266302A Abandoned AU2003266302A1 (en) 2002-08-23 2003-08-21 Method for the diagnosis of alzheimer disease

Country Status (2)

Country Link
AU (1) AU2003266302A1 (en)
WO (1) WO2004019045A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (en) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid β (1-42) oligomers, process for their preparation and their use
EP1976877B2 (en) 2005-11-30 2016-10-05 AbbVie Inc. Monoclonal antibodies against amyloid beta protein and uses thereof
CA2628703C (en) 2005-11-30 2019-10-29 Abbott Laboratories Anti-a.beta. globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
EP2124952A2 (en) 2007-02-27 2009-12-02 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
WO2010084150A1 (en) * 2009-01-23 2010-07-29 Proteosys Ag Diagnostic method for detecting neurodegenerative diseases
US8987419B2 (en) 2010-04-15 2015-03-24 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
MX358739B (en) 2010-08-14 2018-09-03 Abbvie Inc Star Amyloid-beta binding proteins.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985581A (en) * 1996-07-25 1999-11-16 The Mclean Hospital Corporation Use of presenilin-1 for diagnosis of alzheimers disease
AU7873200A (en) * 1999-10-08 2001-04-23 Uab Research Foundation Smdf and ggf neuregulin splice variant isoforms and uses thereof
CA2399452A1 (en) * 2000-02-11 2001-08-16 Proteosys Ag. Use of neuregulin-.beta. as an indicator and/or target
EP2418218A1 (en) * 2001-08-06 2012-02-15 ProteoSys AG Neuregulin-Beta isoforms associated with neuronal processes

Also Published As

Publication number Publication date
WO2004019045A2 (en) 2004-03-04
WO2004019045A3 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
AU2003219690A1 (en) Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
AU2003301347A1 (en) Methods for monitoring treatment of disease
AU2003274346A1 (en) Method for prediction of cardiac disease
IL188165A0 (en) Method for the diagnosis of alzheimer's disease
AU2002950878A0 (en) Method for diagnosing disorders
AU2003217275A1 (en) Azabicyclic compounds for the treatment of disease
EP1940373B8 (en) 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease
AU2003219359A1 (en) Imaging method
AU2003254146A1 (en) Methods for the treatment of parkinson's disease
AU2003266302A1 (en) Method for the diagnosis of alzheimer disease
AU2003273310A1 (en) Substituted aminoethers for the treatment of alzheimer's disease
AU2003260983A1 (en) Processes for the preparation of s-(-)-amlodipine
AU2003223780A1 (en) Treatment for pompe disease
AU2003283648A1 (en) Compounds as radioligands for the diagnosis of disease
AU2003201630A1 (en) A method for the diagnosis of lymphoproliferative diseases
AU2002367890A1 (en) Process for the preparation of 4-methyl-thiazole-5-carbaldehyde intermediate
AU2003258622A1 (en) Method for the production of $g(b)-carotinoids
AU2003277202A1 (en) Methods for diagnosing bone turnover disease
AU2003299101A1 (en) Compounds for the treatment of alzheimer's disease
AU2003283732A1 (en) Method of tomographic imaging
AU2003251962A1 (en) Screening for alzheimer's disease
AU2003294206A1 (en) Methods for diagnosing htlv-i-mediated diseases
EP1693671A4 (en) Method of diagnosing alzheimer's disease
AU2002323855A1 (en) Method for diagnosing the functional condition of an organism
AU2003269482A1 (en) Process for the manufacture of 2,1,3-benzoxadiazole-4-carboxaldehyde

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase